发明申请
US20180311372A1 METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)
审中-公开
![METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)](/abs-image/US/2018/11/01/US20180311372A1/abs.jpg.150x150.jpg)
基本信息:
- 专利标题: METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)
- 申请号:US15872841 申请日:2018-01-16
- 公开(公告)号:US20180311372A1 公开(公告)日:2018-11-01
- 发明人: Yuan CHENG , Chawita NETIROJJANAKUL , Jerry Ryan HOLDER , Bin WU , James R. FALSEY , Bradley J. HERBERICH , Kelvin SHAM , Leslie P. MIRANDA , Shu-Chen LU , Murielle VENIANT-ELLISON , Shanaka STANISLAUS , Junming YIE , Jing XU
- 申请人: AMGEN INC.
- 申请人地址: US CA Thousand Oaks
- 专利权人: AMGEN INC.
- 当前专利权人: AMGEN INC.
- 当前专利权人地址: US CA Thousand Oaks
- 主分类号: A61K47/68
- IPC分类号: A61K47/68 ; C07K16/28 ; A61P3/10
摘要:
Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
公开/授权文献:
IPC结构图谱:
A | 人类生活必需 |
--A61 | 医学或兽医学;卫生学 |
----A61K | 医用、牙科用或梳妆用的配制品 |
------A61K47/00 | 以所用的非有效成分为特征的医用配制品,如载体、惰性添加剂 |
--------A61K47/50 | .非有效成分被化学键合到有效成分上,例如聚合物-药物结合物 |
----------A61K47/66 | ..该改性剂是靶向特定细胞的涉及肽或蛋白质的预靶向系统 |
------------A61K47/68 | ...该改性剂是抗体、免疫球蛋白或其片段,例如Fc-片段 |